Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity

Reuters

06/18

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity

SEATTLE, WA / ACCESS Newswire / June 18, 2025 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia $(AML.AU)$ patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544974035"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544974035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544974035?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544974035","market":"us","top_or_hot":-1,"title":"Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SEATTLE, WA / ACCESS Newswire / June 18, 2025 - <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SEATTLE, WA / ACCESS Newswire / June 18, 2025 - <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL18xCyp:1","article_id":"2544974035","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544974035","pubTimestamp":1750248111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 18, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APVO":"Aptevo Therapeutics Inc.","BK4583":"猴痘概念","EBS":"Emergent Biosolutions"},"translate_title":"Aptevo Therapeutics宣布Mipletamig治疗一线AML的有希望的1b/2期试验结果，在没有增加毒性的情况下实现了85%的缓解率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9,"EBS":0.9},"content_text":"Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity\n    \n\n        SEATTLE, WA / ACCESS Newswire / June 18, 2025 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia $(AML.AU)$ patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}